RMD Resmed

[Joshuatree]

Bought some yest ;have bounced today.Last i looked FPH hadn't; could be an op.

[Joshuatree]

I took profits a few weeks back and hope to buy back in soon. Premier company,shares the bulk of U.S mkt share with one other co, FPH a tiddler. Camden55 's posts on H/C has facts you may be int in.

[Joshuatree]

Its a Circus there :laugh::t_up::t_down::lol::sneaky2:

[Joshuatree]

Below $5 today. Am selling a few FPH and picking up a few again. Looks like the $NZ/$ ASXexchange rate is somewhere near a top. too.

[Joshuatree]

Nearly a year later and re $7 nice. Weak $A good.

[Joshuatree]

Been a marvellous money for jam ride.Just coming off a bit atm @A$9.42. A quick 1 year calc tells me RMD up re 87.6% in $A and FPH nz up re 85.7%. been a great sector. to be in. SOM up re 60.6% and CMP up re 109% ; doubled since march.

[Joshuatree]

DOH ! ive hexed the price agaiN!:eek2: $8.13 yest. Big overreaction to quarterly results . Im placing a buy today to double my holdings. Looks like it ticked up in the US last nite but haven't verified last sale atp. Still a longterm anchor stock for my portfolio.

[Joshuatree]

Closed up 0.2% hardly conclusive, will watch the depth.

[dingoNZ]

Closed up 0.2% hardly conclusive, will watch the depth.


Agree with you Joshuatree, LT nothing has changed, margins are tighter short term but, IMO this just presents a buying opportunity. They are the market leader and have a strong market share over FPH and are yonks ahead on the research and products ready to market front.

Good buying down here IMO

[Joshuatree]

Very unexpected news , not so good.I don't think it affects their main market ; but another potentially lucrative mkt has been stopped dead in its tracks.

http://www.smh.com.au/business/resm...putting-patients-at-risk-20150513-gh10qs.html (http://www.smh.com.au/business/resmed-heart-attack-trial-stopped-after-putting-patients-at-risk-20150513-gh10qs.html)

[Joshuatree]

Hammered today dingo ;currently $6.73 , low so far $6.69 re 40 mill shares thru. Hows my timing:eek2: Thinking of topping up. Few companies of this mkt cap have the long term track record of RMD.

[Joshuatree]

Increased my holdings by 25% yest @ $6.73 ;am still in the black(bought first third a while back) but much less so.Closed at $6.99 today. Could be more ops;s/p recovery may take a while.

[Toulouse - Luzern]

Hi Joshuatree,

Looks like SP is rising.

Indicated right now to open at $7.02.

So up 33 cents from the low or 5% ish and 4.3% in your case ...

I read the report on the trial.

The headlines and some broker recommendations have impacted the SP (eg The Bull today)

My recollection is that it was a smallish trial and it was of people who had already experienced heart failure ...

[Joshuatree]

Yeah TL a blip on the longterm rise and a rare chance to average down. Ive ordered myself not to meddle with stocks like these and that its the sitting that will increase my wealth.

This from a very knowledgeable person.

"This is a company whose market value has, over the last two decades almost , risen by an average rate in excess of 25% pa. This has been supported by compound annual growth rates for rev,EBITDA and NPAT of 20%,22%and 25% pa , respectively".

No reason why the next decade won't be the same for this industry leader, esp with the world currently getting fatter.

[Joshuatree]

ResMed – An Alternative Perspective (http://asxlongtail.com/2015/05/18/resmed-an-alternative-perspective/)

[cloggs]

Good article. $7.25 now.

[Joshuatree]

Supreme court saves Obamacare. This is good for RMD and FPH re funding in the states

[Joshuatree]

Trump dealing to Obamacare.Whats going to happen to the 20-30 million folks who won't be able to afford health insurance?
Meanwhile RMD up 7% on results today

ResMed Announces Results for the Second Qtr of FY 2017 (https://hotcopper.com.au/threads/3180854/)
Dividend/Distribution - RMD

[Joshuatree]

ResMed Announces Results for the Second Qtr of FY 2018 (https://hotcopper.com.au/threads/3974314/)

And up re 8% to a new high, $12 on results today:)

[Joshuatree]

New all time high $15.90 today .PE 53 plus!! (on ASB). Flicked a few off for some cash.

[Joshuatree]

Slightly above forecasts ive read and div the same , 37c. S/P up on nasdaq.
ASX $13.75 atm. Add on later.S/P up re 6% today :).

First Quarter 2019 Highlights


 Revenue increased 12% to $588.3 million; up 13% on a constant currency basis
 Net income increased by 23%; non-GAAP net income up 23%
 GAAP diluted earnings per share of $0.73; non-GAAP diluted earnings per share of $0.81

[Joshuatree]

Not far off its high atm wheres FPH is 25% down.

[Joshuatree]

Good result yet again , but is it enough ,S/P at an all time high.

Second Quarter 2019 Highlights


Revenue increased 8% to $651.1 million; $588.3 mill last qtr, up 9% on a constant currency basis

Gross Margin expanded 70bps to 58.9%

Net operating profit increased 8%; non-GAAP operating profit up 15%

GAAP diluted earnings per share of $0.86; non-GAAP diluted earnings per share of $1.00

[Joshuatree]

Nope ,down 9% atpit.

[RupertBear]

I am viewing the drop as a buying opportunity, topped up at $14.63 ;)

[Toulouse - Luzern]

I saw an interview with CEO on CNBC with Mandy Drury after the announcement.
Announcement was positive overall.
Negatives included minor misses of some expectations and their share buy back programme was halted.
CEO explained they had made $1.5B aquisitions and wanted trading to restore cash before resuming SBB. They have suspended SBB before after aquisitions.

This year takeovers included Matrixcare and Bright Tree health software. Resmed launched new products Moby (?) a liteweight portable oxygen supply innovation where Resmed will supply the unobtrusive face masks. This will enable house bound elderly requiring oxygen to go shopping etc. CEO explained people will spend on devices that provide health and life style benefits, even in bad times.

He also spoke of the new improved Resmed masks M30-1 and F30.

Above from memory E&OE. Decided at this point to find the video and post the link.

At face value positive for SPP as acquisitions additional revenue increases.

https://www.cnbc.com/video/2019/01/24/how-resmed-is-moving-away-from-hospital-health-care.html

Apologies as CNBC clips usually have an ad before they run ...

[RupertBear]

I am viewing the drop as a buying opportunity, topped up at $14.63 ;)

Down another 10% :scared: ouch! Should have known better than trying to catch the falling knife!! :(

[Joshuatree]

I sold some more @$15.91. They were priced for perfection (and have been on a pedestal for some time), whether they rerate back up there to their lofty PE heights for a best in breed stock im not so sure in 2019 because of the uncertainty re the mkts on a slide down this year.? I hope they do rerate, in a flight to quality/safety sorta way. FPH dragged down too.

[RupertBear]

I sold some more @$15.91. They were priced for perfection (and have been on a pedestal for some time), whether they rerate back up there to their lofty PE heights for a best in breed stock im not so sure in 2019 because of the uncertainty re the mkts on a slide down this year.? I hope they do rerate, in a flight to quality/safety sorta way. FPH dragged down too.

I sold some recently at $15.45 and then regretted it so I was quite pleased to buy them back at $14.63, not feeling quite so pleased now but trying to convince myself they will be a good long term hold but hard to know with the current uncertainty. :mellow:

[Joshuatree]

Download Document 84.1KB (https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvSDYL4ga9w Bn%2Fv%2BV0%2B7FiGug%3D)

New high s/p up 14% to $21 (back little now). May take some $ and put more into junior OVN. Over 50% of users give up the cpap masks within a year, OVN offer an alternative.

[percy]

https://stockhead.cmail19.com/t/d-l-zdltrdt-yupddjlly-yk/

[Joshuatree]

From FNArena ,could hurt FPH too.
"Brokers were universally disappointed by ResMed’s ((RMD)) margin outcome in the fourth quarter, though revenues were around the forecast level and margins are expected to improve. Only days after the release, market sentiment received an additional hit as US pharmaceutical Eli Lilly announced a fast-tracked trial for its successful obesity drug, tirzepatide, specifically targeting the CPAP mkt"